PROCTER & GAMBLE Co·4

Feb 13, 6:59 AM ET

Coombe Gary A 4

4 · PROCTER & GAMBLE Co · Filed Feb 13, 2026

Research Summary

AI-generated summary of this filing

Updated

Procter & Gamble CEO Gary Coombe Sells 36,093 Shares After Option Exercise

What Happened
Gary A. Coombe, CEO – Grooming at Procter & Gamble (PG), exercised stock options and immediately sold the resulting 36,093 shares on Feb 12, 2026. He paid $78.52 per share to exercise (cost ≈ $2,834,022) and sold the same 36,093 shares in the open market at a weighted average price of $162.33 for gross proceeds of about $5,859,002. The filing also shows a related derivative disposition entry tied to the exercise and a small earlier RSU-type grant from Nov 17, 2025.

Key Details

  • Transaction date: 2026-02-12 (filed 2026-02-13 — timely filing).
  • Exercise: 36,093 shares at $78.52 → $2,834,022 paid.
  • Sale: 36,093 shares at weighted avg $162.33 → ~$5,859,002 proceeds (price range reported $162.33–$162.35).
  • Related entries: a derivative disposition at $0 associated with the exercise; a prior grant (63.689 units) dated 2025-11-17 (derivative/RSU).
  • Shares owned after the transaction: not specified in the provided filing summary — see the full Form 4 for exact post-transaction holdings.
  • Footnotes: filing references dividend-equivalent RSUs and dividend reinvestment adjustments (see footnotes F1–F6 in the filing for details).

Context

  • This was a cashless exercise: shares were acquired via exercise of a derivative (option/award) and the same shares were sold immediately in the open market. Such transactions commonly reflect routine liquidity or tax-withholding actions rather than a directional view on the stock.
  • Derivative entries in the filing reflect the mechanics of exercising awards and settling related units; consult the full Form 4 for complete tax-withholding or retirement-delivery details.

Insider Transaction Report

Form 4
Period: 2026-02-12
Coombe Gary A
CEO - Grooming
Transactions
  • Exercise/Conversion

    Common Stock

    [F1][F2]
    2026-02-12$78.52/sh+36,093$2,834,02271,086.789 total
  • Sale

    Common Stock

    [F3]
    2026-02-12$162.33/sh36,093$5,859,00234,993.789 total
  • Award

    Restricted Stock Units

    [F5][F6]
    2025-11-17+63.6891,117.366 total
    Common Stock (63.689 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2026-02-1236,09336,093 total
    Exercise: $78.52From: 2021-02-26Exp: 2028-02-28Common Stock (36,093 underlying)
Holdings
  • Common Stock

    [F4]
    (indirect: By Trust)
    486.434
  • Common Stock

    (indirect: International Stock Ownership Plan & Pension Plan (Switzerland))
    1,295.35
Footnotes (6)
  • [F1]Total includes grant of dividend equivalents in the form of Restricted Stock Units (RSU's) settled in common stock.
  • [F2]Total includes grant of dividend equivalents in the form of Restricted Stock Units (RSU's) and shares acquired through the issuer's dividend reinvestment plan.
  • [F3]Weighted average price of the shares sold. The price range was $162.33 to $162.35. Full information regarding the number of shares sold at each separate price available upon request.
  • [F4]Reflects adjustment to PST through December 31, 2025.
  • [F5]Dividend equivalents in the form of Restricted Stock Units (RSUs) previously awarded pursuant to issuer's retirement program. All such RSUs represent a contingent right to receive Procter & Gamble common stock.
  • [F6]These units will deliver in shares on retirement from the company, unless delivery is deferred or such shares are contributed to reporting person's deferred compensation account.
Signature
/s/ Wednesday Shipp, attorney-in-fact for Gary A. Coombe|2026-02-13

Documents

1 file
  • 4
    form4.xmlPrimary

    PRIMARY DOCUMENT